Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Furie

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Rheumatic Diseases Clinics of North America|March 1, 2006
Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosusRichard Furie
The Lancet. Rheumatology|January 26, 2024
Anifrolumab in lupus: the promise and the caution - Author's replyRichard Furie
Immunotherapy|April 3, 2020
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerationsErik Anderson, Richard Furie
Current Opinion in Rheumatology|June 18, 2016
Update on clinical trials in systemic lupus erythematosusSonali Narain, Richard Furie
Best Practice & Research. Clinical Rheumatology|December 12, 2017
Systemic lupus erythematosusRichard Furie, Ricard Cervera
Lancet (London, England)|June 11, 2019
Novel paradigms in systemic lupus erythematosusThomas Dörner, Richard Furie
Rheumatic Diseases Clinics of North America|November 10, 2012
Comparative safety of therapies in systemic lupus erythematosusJoseph Mosak, Richard Furie
Current Rheumatology Reports|April 27, 2012
Belimumab is approved by the FDA: what more do we need to know to optimize decision making?Diane Lewis Horowitz, Richard Furie
Clinical Rheumatology|December 13, 2018
Inflammatory arthritis: a unique presentation of human anaplasmosisLara El Khoury, Richard Furie
Immunotherapy|October 25, 2023
The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosusYoung Min Cho, Richard Furie
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Rheumatic Diseases Clinics of North America|March 1, 2006
Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosusRichard Furie
The Lancet. Rheumatology|January 26, 2024
Anifrolumab in lupus: the promise and the caution - Author's replyRichard Furie
Immunotherapy|April 3, 2020
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerationsErik Anderson, Richard Furie
Current Opinion in Rheumatology|June 18, 2016
Update on clinical trials in systemic lupus erythematosusSonali Narain, Richard Furie
Best Practice & Research. Clinical Rheumatology|December 12, 2017
Systemic lupus erythematosusRichard Furie, Ricard Cervera
Lancet (London, England)|June 11, 2019
Novel paradigms in systemic lupus erythematosusThomas Dörner, Richard Furie
Rheumatic Diseases Clinics of North America|November 10, 2012
Comparative safety of therapies in systemic lupus erythematosusJoseph Mosak, Richard Furie
Current Rheumatology Reports|April 27, 2012
Belimumab is approved by the FDA: what more do we need to know to optimize decision making?Diane Lewis Horowitz, Richard Furie
Clinical Rheumatology|December 13, 2018
Inflammatory arthritis: a unique presentation of human anaplasmosisLara El Khoury, Richard Furie
Immunotherapy|October 25, 2023
The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosusYoung Min Cho, Richard Furie
Pageof 10